诱导化疗在进展期头颈部鳞癌中的应用现状和研究进展

张泽; 张仑; 王旭东

doi:10.12354/j.issn.1000-8179.2021.20211160

诱导化疗在进展期头颈部鳞癌中的应用现状和研究进展

doi: 10.12354/j.issn.1000-8179.2021.20211160

天津医科大学肿瘤医院颌面耳鼻喉肿瘤科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心（天津市300060）

基金项目: 本文课题受国家自然科学基金项目（编号：81902757）和天津医科大学肿瘤医院临床试验基金项目（编号：C1715/C1716）资助

详细信息

作者简介:
张泽：专业方向为头颈部肿瘤的基础研究和临床诊治

通讯作者:
王旭东　wxd.1133@163.com

计量
- 文章访问数: 177
- HTML全文浏览量: 67
- PDF下载量: 32
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-30
- 录用日期: 2021-11-18
- 网络出版日期: 2022-01-25

Research progress of induction chemotherapy in advanced head and neck squamous cell carcinoma

Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China

Funds: This work was supported by the Natural Science Foundation of China (No. 81902757) and Clinical Trial Foundation of Tianjin Medical University Cancer Institute and Hospital （No. C1715/C1716）

More Information

Corresponding author: Xudong Wang; E-mail: wxd.1133@163.com

摘要

摘要: 头颈部鳞状细胞癌（head and neck squamous cell carcinoma，HNSCC）是常见的恶性肿瘤。诱导化疗作为治疗进展期HNSCC的主要手段之一，得到广泛研究并应用于临床。然而，除了在器官保留方面以外，诱导化疗能否为患者带来获益一直存在争议。目前，TPF方案（多西他赛+顺铂+5-氟尿嘧啶）仍然是HNSCC诱导化疗的标准方案，但是TPF方案具有不良反应较大等问题。近年来，围绕着诱导化疗在进展期HNSCC的应用，产生较多的研究报道和循证医学证据。本文通过非系统性检索近年来所有进展期HNSCC诱导化疗的文献，就该领域研究现状进行综述，探讨诱导化疗标准方案的建立和其对患者生存及器官保留的临床意义，总结减少化疗相关不良反应的尝试，分析新的诱导化疗方案。
- 头颈部鳞癌 /
- 诱导化疗 /
- TPF方案 /
- 器官保留 /
- 毒性
Abstract: Head and neck squamous cell carcinoma (HNSCC) is a common malignancy. Induction chemotherapy in advanced HNSCC has been extensively investigated. However, the role of induction chemotherapy outside of laryngeal preservation is unclear. Presently, docetaxel-cisplatin-fluorouracil (TPF regimen) is still the standard regimen for induction chemotherapy. Recently, more evidence has been accumulated regarding the application of induction chemotherapy in locally advanced HNSCC. In this review, we non-systematically evaluated recently published studies on induction chemotherapy in various patient populations with locally advanced HNSCC, providing an overview of the effect of induction chemotherapy on survival results and organ preservation, the exact patient subgroups who may benefit from induction chemotherapy, and how to reduce toxicity and which new regimens present promising results.
- squamous cell carcinoma of the head and neck (HNSCC) /
- induction chemotherapy /
- TPF regimen /
- organ preservation /
- toxicity

HTML全文

参考文献(35)

[1]	Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1):92. doi: 10.1038/s41572-020-00224-3
[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660
[3]	Budach V, Tinhofer I. Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review[J]. Lancet Oncol, 2019, 20(6):e313-e326. doi: 10.1016/S1470-2045(19)30177-9
[4]	Okano S, Homma A, Kiyota N, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck[J]. Jpn J Clin Oncol, 2021, 51(2):173-179. doi: 10.1093/jjco/hyaa220
[5]	Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007, 357(17):1695-1704. doi: 10.1056/NEJMoa071028
[6]	Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J]. N Engl J Med, 2007, 357(17):1705-1715. doi: 10.1056/NEJMoa070956
[7]	Haddad RI, Posner M, Hitt R, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions[J]. Ann Oncol, 2018, 29(5):1130-1140. doi: 10.1093/annonc/mdy102
[8]	Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891[J]. Ann Oncol, 2012, 23(10):2708-2714. doi: 10.1093/annonc/mds065
[9]	Janoray G, Pointreau Y, Garaud P, et al. Long-term results of a multicenter randomized phase Ⅲ trial of induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation[J]. J Natl Cancer Inst, 2016, 108(4):368.
[10]	Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer[J]. J Clin Oncol, 2013, 31(7):845-852. doi: 10.1200/JCO.2012.43.6097
[11]	Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(3):257-264. doi: 10.1016/S1470-2045(13)70011-1
[12]	Cohen EE, Karrison TG, Kocherginsky M, et al. Phase Ⅲ randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer[J]. J Clin Oncol, 2014, 32(25):2735-2743. doi: 10.1200/JCO.2013.54.6309
[13]	Geoffrois L, Martin L, De Raucourt D, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase Ⅲ randomized trial[J]. J Clin Oncol, 2018, 36(31):3077-3083. doi: 10.1200/JCO.2017.76.2591
[14]	Merlano MC, Denaro N, Vecchio S, et al. Phase Ⅲ randomized study of induction chemotherapy followed by definitive radiotherapy + cetuximab versus chemoradiotherapy in squamous cell carcinoma of head and neck: the INTERCEPTOR-GONO study (NCT00999700)[J]. Oncology, 2020, 98(11):763-770. doi: 10.1159/000507733
[15]	Zhong LP, Zhang CP, Ren GX, et al. Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6):744-751. doi: 10.1200/JCO.2012.43.8820
[16]	Han HR, Ma SJ, Hermann GM, et al. Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer[J]. Ann Transl Med, 2021, 9(10):913. doi: 10.21037/atm-20-5032
[17]	Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase Ⅱ-Ⅲ trial[J]. Ann Oncol, 2017, 28(9):2206-2212. doi: 10.1093/annonc/mdx299
[18]	Petit C, Lacas B, Pignon JP, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis[J]. Lancet Oncol, 2021, 22(5):727-736. doi: 10.1016/S1470-2045(21)00076-0
[19]	Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19, 805 patients, on behalf of MACH-NC Group[J]. Radiother Oncol, 2021, 156:281-293. doi: 10.1016/j.radonc.2021.01.013
[20]	Dagan O, Moore A, Nachalon Y, et al. Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience[J]. Head Neck, 2020, 42(11):3118-3124. doi: 10.1002/hed.26353
[21]	Hitt R, Iglesias L, Lopez-Pousa A, et al. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial[J]. Clin Transl Oncol, 2021, 23(4):764-772. doi: 10.1007/s12094-020-02467-8
[22]	Abdelmeguid AS, Silver NL, Boonsripitayanon M, et al. Role of induction chemotherapy for oral cavity squamous cell carcinoma[J]. Cancer, 2021, 127(17):3107-3112. doi: 10.1002/cncr.33616
[23]	Guo TW, Saiyed F, Yao C, et al. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation[J]. Cancer, 2021, 127(16):2916-2925. doi: 10.1002/cncr.33491
[24]	Ferrari D, Ghi MG, Franzese C, et al. The slippery role of induction chemotherapy in head and neck cancer: myth and reality[J]. Front Oncol, 2020, 10:7. doi: 10.3389/fonc.2020.00007
[25]	Bernadach M, Lapeyre M, Dillies AF, et al. Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers[J]. BMC Cancer, 2021, 21(1):360. doi: 10.1186/s12885-021-08128-5
[26]	Tousif D, Sarathy V, Kumar R, et al. Randomized controlled study comparing efficacy and toxicity of weekly vs. 3-weekly induction chemotherapy in locally advanced head and neck squamous cell carcinoma[J]. Front Oncol, 2020, 10:1284. doi: 10.3389/fonc.2020.01284
[27]	Hsieh CY, Lein MY, Yang SN, et al. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase Ⅱ study[J]. BMC Cancer, 2020, 20(1):832. doi: 10.1186/s12885-020-07347-6
[28]	Shirasu H, Yokota T, Kawakami T, et al. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil[J]. Int J Clin Oncol, 2020, 25(11):1914-1920. doi: 10.1007/s10147-020-01742-6
[29]	Lee YG, Kang EJ, Keam B, et al. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01)[J]. BMC Cancer, 2020, 20(1):813. doi: 10.1186/s12885-020-07297-z
[30]	Sun Y, Guo W, Bai Y, et al. Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study[J]. Oral Dis, 2020, 26(2):285-294. doi: 10.1111/odi.13252
[31]	Oppelt P, Ley J, Daly M, et al. nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial[J]. Med Oncol, 2021, 38(4):35. doi: 10.1007/s12032-021-01479-w
[32]	Johnson K, Ley J, Oppelt P, et al. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma[J]. Med Oncol, 2019, 36(11):93. doi: 10.1007/s12032-019-1318-5
[33]	Keil F, Hartl M, Altorjai G, et al. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial[J]. Eur J Cancer, 2021, 151:201-210. doi: 10.1016/j.ejca.2021.03.051
[34]	Li X, Fang Q, Du W, et al. Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma[J]. BMC Cancer, 2021, 21(1):622. doi: 10.1186/s12885-021-08373-8
[35]	Semrau S, Gostian AO, Traxdorf M, et al. Implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer[J]. Cancers (Basel), 2021, 13(8):1959. doi: 10.3390/cancers13081959